Navigation Links
Bioarray Genetics Receives $4M in Series B Equity Financing
Date:10/5/2017

Bioarray Genetics, a personalized medicine startup, announced today that it has received $4 million in Series B Equity Financing from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations.

Bioarray, a personalized medicine startup housed at UConn’s Technology Incubation Program (TIP) in Farmington, is a molecular diagnostics company developing predictive cancer treatment test technology. The platform, consisting of unique genes and proprietary algorithms, provides patient-specific information to determine the optimal course of treatment.
Bioarray will use this funding to bring their first product, BA100, to clinicians and conduct R&D on other tests in the company’s pipeline, including those focused on treatments for metastatic breast and colon cancers.

“Bioarray’s unique approach to developing a diagnostic test is an excellent example of how genomics is advancing personalized medicine. BA100 has the potential to impact oncology care, in the very short term, by sparing patients exposure to ineffective chemotherapy and unnecessary toxicity.  Bioarray’s clinically validated tests are unique; there is nothing else on the market that addresses this need,” said Karimah Es Sabar, Chief Executive Officer of Quark Venture and Director of GHS Fund.

BA100 is a breast cancer diagnostic test that provides actionable information about patient response to the standard of care chemotherapy treatment. BA100 is able to identify the population of triple negative breast cancer patients that have the worst survival rates and would benefit from more aggressive treatment. Bioarray’s test isolates RNA biomarkers from the initial tumor biopsy, and in combination with the company’s proprietary algorithms, can predict the patient’s response prior to treatment.

Currently, this test is intended for patients with stage 1, 2, and 3 non-metastatic breast cancer, and is administered immediately after diagnosis before the doctor decides on the patient’s treatment plan.

“We invested in Bioarray at the earliest stages of company development,” said Pauline Murphy, senior managing director of investments at Connecticut Innovations. “We’re excited to see the company progress to this stage and we look forward to their continued success in the future.”

According to Bioarray’s CEO and Founder, Marcia Fournier, this funding provides the startup with critical support to continue development of a technology that reduces healthcare costs and improves patients’ quality of life.
“This new funding enables Bioarray to fulfill our mission to eliminate the trial and error approach in the treatment of cancer patients. We are excited about our growth and the ability to expand our team with diversified skills and expertise,” said Fournier.

Originally based in Cambridge, Massachusetts, Bioarray chose to locate their startup in Connecticut because of the vibrant entrepreneurial ecosystem and robust state investment in bioscience, according to Fournier. She credits UConn’s Technology Incubation Program with allowing her to transition from a virtual company.

“UConn is committed to supporting growing technology startups that will help continue to position Connecticut as a hub for bioscience,” said Radenka Maric, UConn’s vice president for research. “From world-class faculty experts to state-of-the-art facilities to our proximity to The Jackson Laboratory for Genomic Medicine—UConn has a tremendous amount to offer these companies.”

Bioarray plans to explore other applications for their platform technology, which could serve as a valuable tool for pharmaceutical companies in the drug research and development process. The technology provides novel insight into the mechanism of response and interconnected cellular pathways and could be used to stratify patients in clinical trials, as well as develop companion diagnostics to improve the response rate to specific treatments.

About Global Health Science Fund
Global Health Science Fund was jointly established by Quark Venture Inc. and GF Securities in late 2016. Global Health Science Fund is a health sciences venture fund that invests globally in a diversified portfolio of innovative biotechnology and health sciences companies who are addressing unmet medical needs through innovations in drug development, medical devices, health IT and emerging convergent technologies.

About Connecticut Innovations
Connecticut Innovations (CI) is the leading source of financing and ongoing support for Connecticut's innovative, growing companies. To maximize each business’ growth potential, CI tailors its solutions and often combines its funds with resources from other financial leaders to provide venture capital and strategic support for early-stage technology companies; grants that support innovation and collaboration; and connections to its well-established network of partners and professionals. For more information, please visit http://www.ctinnovations.com.

About UConn’s Technology Incubation Program (TIP)
UConn’s Technology Incubation Program (TIP) is the only university-based technology business incubation program in Connecticut. Established in 2004, TIP couples UConn's world-class research resources, facilities, and business support services with a network of experienced investors and entrepreneurs to help launch high-potential startups. Since 2004, the program has helped over 90 companies that have raised more than $50 million in grants and $135 million in equity and debt. https://tip.uconn.edu/

Read the full story at http://www.prweb.com/releases/2017/10/prweb14773011.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
2. CNA Finance Initiates Research Coverage On Cancer Genetics
3. PreventionGenetics Receives New York License for Genetic Tests
4. Leading Family Genomics Company Good Start Genetics Expands Payor Relationships to More than 130 Million Covered Lives
5. New CAST Issue Paper: "Plant Breeding and Genetics"
6. Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
7. Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
8. Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
9. Preimplantation Genetics Diagnosis Market to Reach $121.50 Million, by 2022, Globally - Allied Market Research
10. Important Information Regarding the Genetics of Alzheimer’s Disease and Dementia Announced by One Million Solutions in Health™
11. Atlas Genetics Raises $35m in Series D Fundraising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):